Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Pacira Pharmaceuticals (NASDAQ: PCRX)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRKResearch Report) and Pacira Pharmaceuticals (PCRXResearch Report) with bullish sentiments.

Merck & Company (MRK)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company today and set a price target of $100.00. The company’s shares closed last Tuesday at $82.84.

According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.0% and a 38.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Merck & Company has an analyst consensus of Strong Buy, with a price target consensus of $95.63.

See today’s analyst top recommended stocks >>

Pacira Pharmaceuticals (PCRX)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $85.00. The company’s shares closed last Tuesday at $59.03, close to its 52-week high of $64.44.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 11.5% and a 48.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Catabasis Pharmaceuticals, and Eiger Biopharmaceuticals.

Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $65.83, which is a 10.2% upside from current levels. In a report released yesterday, Northland Securities also upgraded the stock to Buy with a $67.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.